Skip to main content
Midas Edge

ATOSSA THERAPEUTICS INC

For the period ended Mar 31, 2024. Filed May 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

ATOS$2.14+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Cash Flows

(amounts in thousands)

For the Three Months Ended March 31,
20242023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss$(5,878)$(6,281)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation4171,573
Loss on disposal of assets2—
Depreciation53
Changes in operating assets and liabilities:
Prepaid materials115414
Prepaid expenses and other current assets549(108)
Other assets—1
Accounts payable424(1,521)
Accrued expenses640(446)
Payroll liabilities(995)(703)
Other current liabilities2346
Net cash used in operating activities(4,698)(7,022)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment(6)—
Net cash used in investing activities(6)—
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants204—
Net cash provided by financing activities204—
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH(4,500)(7,022)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE88,570111,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE$84,070$103,978
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents83,960103,868
Restricted cash110110
Total cash, cash equivalents and restricted cash$84,070$103,978
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.